Biocytogen and Whitehawk Partner on Bispecific ADC Development
Event summary
- Biocytogen and Whitehawk Therapeutics have entered a global collaboration to develop bispecific antibody-drug conjugates (BsADC).
- Biocytogen will provide access to up to five bispecific antibodies using its RenLite® platform.
- Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies.
- Biocytogen receives an upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as low single-digit royalties on net sales.
The big picture
This partnership underscores the growing trend of biotech companies leveraging complementary technologies to accelerate drug development. Biocytogen’s expertise in bispecific antibodies and Whitehawk’s advanced ADC platform aim to create innovative treatments for difficult-to-treat cancers, reflecting broader industry efforts to enhance targeting strategies in oncology.
What we're watching
- Pipeline Expansion
- Whether Whitehawk can successfully advance BsADC candidates to deliver new ADC INDs within the next 12-24 months.
- Technological Integration
- How effectively Biocytogen’s RenLite® platform and Whitehawk’s ADC linker-payload technologies can be combined to create differentiated therapeutic candidates.
- Commercial Potential
- The pace at which the collaboration can generate commercially viable BsADC candidates, given the competitive landscape in oncology drug development.
Related topics